These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 17908991

  • 1. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.
    Clin Cancer Res; 2007 Oct 01; 13(19):5942-51. PubMed ID: 17908991
    [Abstract] [Full Text] [Related]

  • 2. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.
    Cancer Res; 2007 Mar 15; 67(6):2783-90. PubMed ID: 17363600
    [Abstract] [Full Text] [Related]

  • 3. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 15; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 4. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB.
    Clin Cancer Res; 2003 Oct 01; 9(12):4537-45. PubMed ID: 14555528
    [Abstract] [Full Text] [Related]

  • 5. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 6. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct 21; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE, Rundall BK, Jones DR.
    J Thorac Cardiovasc Surg; 2004 Nov 21; 128(5):740-8. PubMed ID: 15514602
    [Abstract] [Full Text] [Related]

  • 8. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 9. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
    Srimatkandada P, Loomis R, Carbone R, Srimatkandada S, Lacy J.
    Eur J Haematol; 2008 May 15; 80(5):407-18. PubMed ID: 18221384
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K.
    Int J Oncol; 2011 Dec 15; 39(6):1529-36. PubMed ID: 21785822
    [Abstract] [Full Text] [Related]

  • 11. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
    Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, Shyue SK, Liou JY.
    Life Sci; 2010 Jan 30; 86(5-6):199-206. PubMed ID: 20006625
    [Abstract] [Full Text] [Related]

  • 12. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G, Gekeler V, Leja A, Beckers T, Boehm M.
    Cancer Res; 2006 May 15; 66(10):5409-18. PubMed ID: 16707469
    [Abstract] [Full Text] [Related]

  • 13. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S.
    Clin Cancer Res; 2008 Jan 15; 14(2):549-58. PubMed ID: 18223231
    [Abstract] [Full Text] [Related]

  • 14. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M.
    Leukemia; 2004 Aug 15; 18(8):1357-63. PubMed ID: 15190257
    [Abstract] [Full Text] [Related]

  • 15. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Park J, Ahn KS, Bae EK, Kim BS, Kim BK, Lee YY, Yoon SS.
    Anticancer Drugs; 2008 Sep 15; 19(8):777-82. PubMed ID: 18690088
    [Abstract] [Full Text] [Related]

  • 16. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S, Alexiadis M, Fuller PJ.
    Reprod Sci; 2009 Apr 15; 16(4):397-407. PubMed ID: 19087975
    [Abstract] [Full Text] [Related]

  • 17. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.
    Int J Oncol; 2006 Sep 15; 29(3):713-9. PubMed ID: 16865289
    [Abstract] [Full Text] [Related]

  • 18. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells.
    Marín YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J, Lee HJ, Rabson AB, Yang CS, Chen S, Ryu JH.
    Melanoma Res; 2007 Oct 15; 17(5):274-83. PubMed ID: 17885582
    [Abstract] [Full Text] [Related]

  • 19. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.
    Lun M, Zhang PL, Siegelmann-Danieli N, Blasick TM, Brown RE.
    Ann Clin Lab Sci; 2005 Oct 15; 35(1):15-24. PubMed ID: 15830705
    [Abstract] [Full Text] [Related]

  • 20. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.
    Cancer Chemother Pharmacol; 2008 Apr 15; 61(4):549-58. PubMed ID: 17522864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.